logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2022
Gossamer Bio Inc.
Topline data from phase II trial of Seralutinib (TORREY )
Pulmonary Arterial Hypertension
Q3 2022
Freeline Therapeutics Holdings plc
Initial safety and biomarker data from first cohort Phase 1/2 trial of FLT201
Gaucher disease Type 1
2H 2022
Lava Therapeutics B.V.
Top line data from Phase 2a expansion cohorts of LAVA-051
Relapsed and/or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML)
Q3 2022
Rallybio Corp
Data from phase Ib proof-of-concept study of RLYB212
To eliminate transfused HPA-1a positive platelets from the circulation of HPA-1a negative healthy male volunteers
2H 2022
Rallybio Corp
Data from phase I study of RLYB116
Paroxysmal Nocturnal Hemoglobinuria (PNH) and Generalized Myasthenia Gravis (gMG).
2H 2022
Exelixis, Inc.
Initial data from phase III pivotal trial evaluating Cabometyx in combination with Tecentriq (CONTACT-01)
Non-small cell lung cancer
2H 2022
Exelixis, Inc.
Initial data from phase III pivotal trial evaluating Cabometyx in combination with Tecentriq (CONTACT-03)
Renal cell carcinoma
2H 2022
Arcturus Therapeutics Ltd.
Interim data phase II study of ARCT-810
Ornithine Transcarbamylase deficiency
2H 2022
Arcutis Biotherapeutics Inc.
Topline data from phase III trial of Topical Roflumilast cream (INTEGUMENT-1)
Atopic dermatitis
2H 2022
Arcutis Biotherapeutics Inc.
Topline data from phase III trial of Topical Roflumilast cream (INTEGUMENT-2)
Atopic dermatitis
2H 2022
Arcutis Biotherapeutics Inc.
Topline data from phase III trial of Topical Roflumilast cream (INTEGUMENT-PED)
Atopic dermatitis
2H 2022
Arcutis Biotherapeutics Inc.
Topline data from phase III pivotal trial of topical Roflumilast foam
Scalp and body psoriasis
2H 2022
eFFECTOR Therapeutics, Inc.
Topline results rom one or more phase II expansion cohorts of phase I/II trial of Zotatifin
Multiple solid tumors
2H 2022
Roche Holding AG
Pivotal data readout of phase III trials of Gantenerumab
Patients with early Alzheimer's disease
2H 2022
Viracta Therapeutics, Inc.
Preliminary Phase 1b safety and efficacy data from the Phase 1b/2 trial of Nanatinostat
Advanced EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors
2H 2022
Viracta Therapeutics, Inc.
Update on phase 2 clinical trial of Nanatinostat in combination with Valganciclovir as oral combination therapy (NAVAL-1)
Epstein-Barr virus-positive (EBV+) lymphoma
2H 2022
Synlogic Inc
Data from Phase I trial of SYNB1353
Healthy volunteers
2H 2022
X4 Pharmaceuticals, Inc.
Additional data from phase Ib trial of Mavorixafor in combination with ibrutinib
Waldenström’s macroglobulinemia (WM)
Q3 2022
PolyPid Ltd.
Top Line results from second phase III trial of D-PLEX100 (SHIELD II)
Prevention of post-abdominal surgery incisional infection (soft tissue)
2H 2022
Aldeyra Therapeutics, Inc.
Top-line results from phase II clinical trial of ADX-2191
Retinitis pigmentosa
Q3 2022
Akero Therapeutics Inc.
Data from phase 2b clinical trial of Efruxifermin (HARMONY)
Pre-cirrhotic NASH (F2-F3 fibrosis)
Q3 2022
Ascendis Pharma A/S
Topline data from phase I/II study of TransCon TLR7/8 Agonist With or Without Pembrolizumab (TranscendIT-101)
Advanced or metastatic solid tumors
2H 2022
CinCor Pharma Inc.
Topline data from phase II study of CIN-107 (BrigHtn)
Resistant hypertension
2H 2022
CinCor Pharma Inc.
Topline data from phase II trial of CIN-107 (HALO)
Uncontrolled hypertension
2H 2022
Cellectar Biosciences Inc
Top-line data from pivotal study of Iopofosine
Waldenstrom's macroglobulinemia